Patient-derived organoids: a promising model for personalized cancer treatment
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Cancer has remained one of the biggest challenges for human health during the past few decades despite major advances in medicine [1]. Poor prognosis of cancer is mainly caused by a lack of effective treatment. Moreover, many patients cannot receive appropriate treatment despite early diagnosis. High heterogeneity is a tumor characteristic and different types of cancer usually vary in clinical features and tumorigenic mechanisms, which results in different responses to drugs [2]. How to predict accurately the patient’s response to drugs and choose personalized treatment is one of the main concerns of doctors. Cancer cell lines and patient-derived xenograft (PDX) models are widely used as preclinical tumor models for screening drugs and assessing drug responses. Cancer cell lines are derived from primary patient tumors and have contributed greatly to cancer research. Cancer cell lines are able to expand rapidly and are often used for high-throughput drug screening. Moreover, they are amenable to genetic modification, which is necessary for research on mechanisms of cancer development. However, it is clear that histological and genetic features in cancer cell lines have changed a lot compared with those in native tumors [3]. As a result, many drugs that perform well in cancer cell lines finally fail in clinical trials. PDX models are generated by transplanting fresh tumor tissue from patients subcutaneously or orthotopically into immunodeficient mice. They mimic the biological characteristics of the primary tumors better than do cancer cell lines. Although PDX models can better predict drug responses, their application in medicine is limited because they are expensive and time- and resource-consuming [4]. It is necessary to develop a new model that has the advantages of the two models mentioned above. Tumor organoids may be superior models to identify and test novel anticancer drugs. Organoids are 3D cultured multicellular clusters. They are derived from pluripotent stem cells or isolated organ progenitors that differentiate to form an organ-like tissue exhibiting multiple cell types. Organoids have self-renewal and self-organization capabilities and retain the characteristics of the physiological structure and function of their source tumor. Sato et al. [5] placed intestinal stem cells into a gel matrix to mimic the extracellular matrix microenvironment, and finally the stem cells began to divide, differentiate and form structures resembling intestinal villi and crypts. Since then, organoids have been widely studied. Upon embedment into a 3D matrix, tissue-derived tumors from patients can also grow into organoids, termed tumor organoids (Figure 1) [6]. So far, 12 tumor organoids have been established (Table 1) [7–16]. In a recent study, Vlachogiannis and colleagues [7] developed patient-derived organoids (PDOs) derived from 110 metastatic tumor samples from 71 patients with colorectal or gastroesophageal cancer enrolled in phase I/II clinical trials. Phenotypic and genotypic profiling of PDOs was similar to that of the original tumors and they had the same gene-mutation spectrum. Besides, molecular profiling of the tumor organoids was matched to drug-screening results. More importantly, PDOs had 88% accuracy for predicting whether they would respond to some drugs and 100% accuracy for predicting whether they would not. The outcomes of PDOs for predicting treatment are encouraging and suggest that PDOs may be an ideal platform to identify and assess the efficacy of anticancer drugs. Summary of patient-derived organoids Summary of patient-derived organoids Generation of patient-derived organoids. Cancer cells from patients are embedded into a matrix for 3D culture in vitro and they can grow into tumor organoids. Patient-derived organoids mimic the biological characteristics of the primary tumors. PDOs are 3D in vitro models; many studies have shown that they can recapitulate basic features of primary tumors, including histological complexity and genetic heterogeneity of human cancer [7–16]. Hematoxylin and eosin staining shows that PDOs share morphological features with the primary tumor and immunohistochemistry markers used in the diagnosis of specific tumors show that the expression pattern of the tumor is maintained in PDOs [7]. Moreover, PDOs preserve the genomic and transcriptomic characteristics of their primary tumors [7]. For example, mutation status, copy number alteration and identification of fusion genes and transcriptional landscape are similar to those of the primary tumor. These genomic alterations persist even after several months of subsequent culture. Compared with 2D culture models, the 3D models have advantages in gene expression, mutation status, metastatic potential and drug response. PDOs can also be expanded long-term in vitro and used for high-throughput drug screening. These characteristics of PDOs discussed above allow a wide range of potential applications in medicine (Figure 2). Fi
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Sato, T., Stange, D. E., Ferrante, M., Vries, R. G. J., van Es, J. H., van den Brink, S., van Houdt, W. J., Pronk, A., van Gorp, J., Siersema, P. D., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.050 · Cited by 3,753
Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
van de Wetering, M., Francies, H. E., Francis, J. M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.03.053 · Cited by 2,408
Organoid models of human and mouse ductal pancreatic cancer
Boj, S. F., Hwang, C.-I., Baker, L. A., Chio, I. I. C., Engle, D. D., Corbo, V., Jager, M., Ponz-Sarvise, M., Tiriac, H., Spector, M. S., et al. (2015) · Cell · doi:10.1016/j.cell.2014.12.021 · Cited by 2,150
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., et al. (2018) · Science · doi:10.1126/science.aao2774 · Cited by 2,096 · cited 4×
“Hematoxylin and eosin staining shows that PDOs share morphological features with the primary tumor and immunohistochemistry markers used in the diagnosis of specific tumors show that the expression pattern of the tumor is maintained in PDOs [7].”
BackgroundInfluentialA living biobank of breast cancer organoids captures disease heterogeneity
Sachs, N., de Ligt, J., Kopper, O., Gogola, E., Bounova, G., Weeber, F., Balgobind, A. V., Wind, K., Gracanin, A., Begthel, H., et al. (2018) · Cell · doi:10.1016/j.cell.2017.11.010 · Cited by 1,973
Drost, J., & Clevers, H. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0007-6 · Cited by 1,790 · cited 1×
“it is clear that histological and genetic features in cancer cell lines have changed a lot compared with those in native tumors [3].”
ResultOrganoid Cultures Derived from Patients with Advanced Prostate Cancer
Gao, D., Vela, I., Sboner, A., Iaquinta, P. J., Karthaus, W. R., Gopalan, A., Dowling, C., Wanjala, J. N., Undvall, E. A., Arora, V. K., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.016 · Cited by 1,559
Human primary liver cancer–derived organoid cultures for disease modeling and drug screening
Broutier, L., Mastrogiovanni, G., Verstegen, M. M., Francies, H. E., Gavarró, L. M., Bradshaw, C. R., Allen, G. E., Arnes-Benito, R., Sidorova, O., Gaspersz, M. P., et al. (2017) · Nature Medicine · doi:10.1038/nm.4438 · Cited by 1,471
Dijkstra, K. K., Cattaneo, C. M., Weeber, F., Chalabi, M., van de Haar, J., Fanchi, L. F., Slagter, M., van der Velden, D. L., Kaing, S., Kelderman, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.009 · Cited by 1,135
Cited by
Tumor microenvironment: barrier or opportunity towards effective cancer therapy
Tiwari, A., Trivedi, R., & Lin, S.-Y. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00866-3 · Cited by 377
A Beginner’s Guide to Cell Culture: Practical Advice for Preventing Needless Problems
Weiskirchen, S., Schröder, S. K., Buhl, E. M., & Weiskirchen, R. (2023) · Cells · doi:10.3390/cells12050682 · Cited by 148
“They recapitulate basic features of primary tumors including histological complexity and genetic characteristics and are therefore ideally useful to predict the sensitivity toward antitumor drugs or aspects of tumor progression [92].”
BackgroundDevelopment of a miniaturized 3D organoid culture platform for ultra-high-throughput screening
Du, Y., Li, X., Niu, Q., Mo, X., Qui, M., Ma, T., Kuo, C. J., & Fu, H. (2020) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaa036 · Cited by 125
The somatic molecular evolution of cancer: Mutation, selection, and epistasis
Dasari, K., Somarelli, J. A., Kumar, S., & Townsend, J. P. (2021) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2021.08.003 · Cited by 22
Metadata
- Authors
- Yang, H., Sun, L., Liu, M., & Mao, Y.
- Venue
- Gastroenterology Report
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-10-09
- Volume
- 6
- Issue
- 4
- Pages
- 243-245
- ISSN
- 2052-0034 (ISSN-L)
- OpenAlex
- W2899911867
- Cited by
- 96
- References
- 11
- FWCI
- 2.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Patient-derived organoids: a promising model for personalized cancer treatment. https://app.cochat.ai/papers/10.1093/gastro/goy040
- The paper
- Yang, H., Sun, L., Liu, M., & Mao, Y. (2018). Patient-derived organoids: a promising model for personalized cancer treatment. Gastroenterology Report. https://doi.org/10.1093/gastro/goy040
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.